Public Drug Policy for Children in Canada

Overview

Journal CMAJ

Date 2017 Aug 2

PMID 28760835

Citations 10

Authors

Avram E Denburg

Wendy J Ungar

Mark Greenberg

Affiliations

Soon will be listed here.

Citing Articles

Institutional Priority-Setting for Novel Drugs and Therapeutics: A Qualitative Systematic Review.

Wang D, Hassanein M, Razvi Y, Shaul R, Denburg A Int J Health Policy Manag. 2024; 13:7494.

PMID: 38618836 PMC: 11016276. DOI: 10.34172/ijhpm.2024.7494.

Priority-setting for hospital funding of high-cost innovative drugs and therapeutics: A qualitative institutional case study.

Razvi Y, Horwitz S, Cressman C, Wang D, Shaul R, Denburg A PLoS One. 2024; 19(3):e0300519.

PMID: 38498497 PMC: 10947676. DOI: 10.1371/journal.pone.0300519.

Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.

Judd S, Revon-Riviere G, Grover S, Deyell R, Vanan M, Lewis V Cancer Med. 2024; 13(3):e7033.

PMID: 38400668 PMC: 10891445. DOI: 10.1002/cam4.7033.

High-Cost Drug Policies in Canadian Children's Hospitals: An Exploratory Study.

Pucchio A, Rieder M J Pediatr Pharmacol Ther. 2023; 28(4):343-347.

PMID: 37795289 PMC: 10547051. DOI: 10.5863/1551-6776-28.4.343.

Precision oncology for children: A primer for paediatricians.

Cohen-Gogo S, Denburg A, Villani A, Thacker N, Egan G, Simao Rafael M Paediatr Child Health. 2023; 28(5):278-284.

PMID: 37484033 PMC: 10362955. DOI: 10.1093/pch/pxac123.

References

Milne C, Bruss J . The economics of pediatric formulation development for off-patent drugs. Clin Ther. 2008; 30(11):2133-45. DOI: 10.1016/j.clinthera.2008.11.019. View

Noorani H, Husereau D, Boudreau R, Skidmore B . Priority setting for health technology assessments: a systematic review of current practical approaches. Int J Technol Assess Health Care. 2007; 23(3):310-5. DOI: 10.1017/s026646230707050x. View

Abelson J, Giacomini M, Lehoux P, Gauvin F . Bringing 'the public' into health technology assessment and coverage policy decisions: from principles to practice. Health Policy. 2006; 82(1):37-50. DOI: 10.1016/j.healthpol.2006.07.009. View

Rieder M . Drug research and treatment for children in Canada: A challenge. Paediatr Child Health. 2012; 16(9):560-1. PMC: 3223893. DOI: 10.1093/pch/16.9.560. View

Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J . The social value of a QALY: raising the bar or barring the raise?. BMC Health Serv Res. 2011; 11:8. PMC: 3023672. DOI: 10.1186/1472-6963-11-8. View

Williams A . Intergenerational equity: an exploration of the 'fair innings' argument. Health Econ. 1997; 6(2):117-32. DOI: 10.1002/(sici)1099-1050(199703)6:2<117::aid-hec256>3.0.co;2-b. View

Ungar W, Prosser L, Burnett H . Values and evidence colliding: health technology assessment in child health. Expert Rev Pharmacoecon Outcomes Res. 2013; 13(4):417-9. DOI: 10.1586/14737167.2013.815420. View

Nord E, Street A, Richardson J, Kuhse H, Singer P . The significance of age and duration of effect in social evaluation of health care. Health Care Anal. 1996; 4(2):103-11. DOI: 10.1007/BF02251210. View

Stafinski T, Menon D, Philippon D, McCabe C . Health technology funding decision-making processes around the world: the same, yet different. Pharmacoeconomics. 2011; 29(6):475-95. DOI: 10.2165/11586420-000000000-00000. View

10.

Abrahamyan L, Feldman B, Tomlinson G, Faughnan M, Johnson S, Diamond I . Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet. 2016; 172(4):313-331. DOI: 10.1002/ajmg.c.31533. View

11.

Ashcroft R . Current epistemological problems in evidence based medicine. J Med Ethics. 2004; 30(2):131-5. PMC: 1733829. DOI: 10.1136/jme.2003.007039. View

12.

Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S . Off-label prescribing in pediatric outpatients. Pediatrics. 2014; 135(1):49-58. DOI: 10.1542/peds.2014-0764. View

13.

Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns G, Nakamura H . The status of paediatric medicines initiatives around the world--What has happened and what has not?. Eur J Clin Pharmacol. 2011; 68(1):1-10. DOI: 10.1007/s00228-011-1089-1. View

14.

Keren R, Pati S, Feudtner C . The generation gap: differences between children and adults pertinent to economic evaluations of health interventions. Pharmacoeconomics. 2004; 22(2):71-81. DOI: 10.2165/00019053-200422020-00001. View

15.

Ungar W . Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?. Pharmacoeconomics. 2011; 29(8):641-52. DOI: 10.2165/11591570-000000000-00000. View

16.

Weinstein M . A QALY is a QALY--or is it?. J Health Econ. 1988; 7(3):289-90. DOI: 10.1016/0167-6296(88)90030-6. View